Trial
NCT02796144
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of North Carolina, Chapel Hill
Collaborators
Columbia University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Condition
Schizophrenia
Intervention
Lorcaserin
Why stopped
The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-03